Mental health

Pharmacological interventions for children with Disruptive Behaviour Disorders or Conduct Disorder or Oppositional Defiant Disorder

Question 8: What is the effectiveness, safety and role of pharmacological interventions, by non-specialized health care providers, for the broad category of Disruptive Behaviour Disorders (DBDs), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid (but not exclusively) Attention-Deficit Hyperactivity Disorder (ADHD)?

Management of child and adolescent mental disorders

  • Population: children with Disruptive Behaviour Disorders (DBDs), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid (but not exclusively) Attention-Deficit Hyperactivity Disorder (ADHD)
  • Interventions:
    • carbamazepine
    • lithium
    • methylphenidate
    • risperidone
  • Comparison: placebo
  • Outcomes:
    • aggression
    • family/school functioning
    • human rights
    • safety/tolerability issues
    • symptom reduction/clinical improvement
    • treatment satisfaction
    • user satisfaction.

Recommendation(s)

Pharmacological interventions (such as methylphenidate, lithium, carbamazepine and risperidone) should not be offered by non-specialized health care providers to treat Disruptive Behaviour Disorders (DBD), Conduct Disorder (CD), Oppositional Defiant Disorder (ODD) and comorbid Attention-Deficit Hyperactivity Disorder (ADHD). For these conditions, the patients should be referred to specialist before prescribing any medicines.
Strength of recommendation: STRONG

Evidence profile

Share